Table 1

Demographical and clinical characteristics of patients at baseline

Clinical valuesAll patients (n=1066)BMI ≥30 (n=159)BMI <30 (n=907)P value
BMI, median (IQR), kg/m²24.17 (21.55–27.46)33.62 (31.56–36.81)23.39 (21.22–25.83)
sNfL, median (IQR), pg/mL11.49 (7.5–21)8.84 (6.49–18.87)11.87 (7.75–21.09)0.029*
Age, median (IQR), years31 (26–40)33 (28–41)31 (25–41)0.012*
EDSS, median (IQR)1.5 (1–2)2 (1–2)1.5 (1–2)0.001*
No (%)
 SexMale315 (29.5)42 (26.4)273 (30.1)0.348†
Female751 (70.5)117 (73.6)634 (69.9)
 OCBNegative44 (4.2)7 (4.4)37 (4.1)0.856†
Positive542 (50.8)92 (57.9)450 (49.6)
Unknown480 (45)60 (37.7)420 (53.7)
 T2 lesions1–8355 (33.3)50 (31.4)305 (33.6)0.628†
>8697 (65.4)106 (66.7)591 (65.2)
Unknown14 (1.3)3 (1.9)11 (1.2)
 GD enhancementNo593 (55.6)87 (54.7)506 (55.8)0.795†
Yes426 (40)65 (40.9)361 (39.7)
Unknown47 (4.4)7 (4.4)40 (4.5)
 Receiving DMTNo755 (70.8)111 (69.8)644 (71.1)0.909†
Yes287 (26.9)43 (27)244 (26.9)
Unknown24 (2.3)5 (3.2)19 (2.1)
 Relapse before BL03 (0.3)1 (0.6)2 (0.2)0.46†
1621 (58.3)94 (59.1)527 (58.1)
2382 (35.8)52 (32.7)330 (36.4)
>260 (5.7)12 (7.6)48 (5.2)
 Smoking at BLNo712 (66.8)99 (62.3)613 (67.5)0.128†
Yes337 (31.6)59 (37.1)278 (30.7)
Unknown17 (1.6)1 (0.6)16 (1.8)
  • *Mann-Whitney U tests to investigate group differences for metric variables.

  • † χ2 tests to investigate group differences for categorical variables.

  • BL, baseline; BMI, body mass index; CIS, clinically isolated syndrome; DMT, Disease-modifying therapy; EDSS, Expanded Disability Status Scale; GD, Gadolinium; OCB, oligoclonal bands; RRMS, relapsing-remitting multiple sclerosis; sNfL, serum neurofilament light chain.